Treatment of Mild to Moderate Depression Symptoms in Patients With Spinal Cord Injury

Spinal Cord Injury Clinical Trial

Official title:

Treatment of Mild to Moderate Depression Symptoms in Patients With Spinal Cord Injury

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00735670
• Other study ID #: NDNO60032SS
• Secondary ID: NIDRRH133N060032
• Status: Completed
• Phase: N/A
• First received: August 14, 2008
• Last updated: October 7, 2016
• Start date: June 2008
• Est. completion date: August 2012

Study information

• Verified date: October 2016
• Source: University of Michigan
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

This study was initially designed to test the efficacy of Venlafaxine HCl in reducing incidence of the onset of major depression after a new spinal cord injury (SCI). After several protocol modifications, the purpose of the study is to test the effectiveness of a sub-therapeutic dose of Venlafaxine HCl to reduce mild to moderate symptoms in persons with SCI.

Description:

The successes of psychological and pharmacological modes of intervention in treating depression, both alone and combined, are well documented in the literature. While a great deal of research has identified specific clinical indications for many antidepressants currently available in the general population, little is known about the clinical indications of these agents in SCI. This study is proposed to test the benefits of Venlafaxine HCI (Effexor XR) for reducing mild to moderate symptoms of depression among people with SCI. The intervention will last 12 weeks and there will be 13 assessments and data collection points. Data will be collected at 26 weeks also. Eight face to face contacts are anticipated.

Because of the change in protocol to reducing mild to moderate symptoms and substantially lower enrollment than anticipated (1/6th of what we anticipated), we deleted a number of study outcomes listed in the 2011 posting of this study. Most of these were not part of the original posting in 2008, and those that were deleted were no longer relevant to new protocol's focus on reducing mild to moderate depression. The two outcomes reported here were most relevant to the revised protocol.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: August 2012
• Est. primary completion date: June 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Having sustained an SCI at least six months prior to enrollment.

• Neurological impairment ASIA Grades A-D.

• Mild to moderate depressive symptoms.

• English speaker

• Age 18 years or older

• Able to communicate with study personnel

Exclusion Criteria:

• No neurological impairment due to SCI.

• Presence of cognitive deficits precluding and giving informed consent and completion of survey based assessment tools.

• Psychiatric contraindications (suicidal ideation, history of suicidal attempts, alcohol and drug dependency, other psychiatric diagnosis including bipolar disorder).

• Medical contraindications (terminal illness or unstable medical condition as determined by medical history and/or examination).

• Pregnant or unwilling to use birth control if female and sexually active.

• Presence of glaucoma.

• Prior use of study drug without success or being treated with another antidepressant medication and being unwilling to taper off to take the stud drug.

• Willing to travel to Ann Arbor Michigan.

• Expecting to take or currently taking another experimental study within 30 days

• Major surgery scheduled within 12 weeks

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Depression
• Spinal Cord Injuries
• Spinal Cord Injury
• Wounds and Injuries

Intervention

Drug:
• Venlafaxine HCl
Starting dose is 37.5 mg and ending dose is 150 mg at 13 weeks. From weeks 13 to 26 subjects no longer will receive the drug

Other:
• Placebo
Subjects received a placebo instead of Venlafaxine HCl until week 13 as did the Venlafaxine group.

Locations

Country	Name	City	State
United States	University of Michigan Model SCI Care System	Ann Arbor	Michigan

Sponsors (2)

Lead Sponsor	Collaborator
University of Michigan	U.S. Department of Education

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	16-Item Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR16)	The QIDS assesses symptoms of depression across the nine DSM-IV criterion domains for major depressive episode. The primary end-point in this study was the number of participants who had a >50% change in scores on the QIDs from baseline to week 13 (end of treatment period).	Baseline and Week 13	No
Secondary	Depression Scale of the Patient Health Questionnaire (PHQ-9)	The nine items of the PHQ-9 are based directly on the nine diagnostic criteria for major depressive disorder in the DSM-IV. Higher total scores indicate more severe symptomatology, ranging from 0 (no symptoms) to 27 (most severe symptoms). Data in the tables begin with the overall mean for each group that includes all subjects, average across all assessment time points. Each subsequent row reports the mean and standard deviation of each time point by allocation, noting sample size for each group in the arm/group title given missing data in each time point after baseline.	Baseline and weeks 1, 2, 3, 5, 9, 13, 14, 15, 16, 18, 20 and 26 weeks	No